secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ernexa Therapeutics Inc. (ERNA)
CIK:        0000748592
Form:       8-K
Filed at:   2023-07-13T23:59:59+00:00
Accession:  0001140361-23-034310
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eterna Therapeutics amends Factor license: adds veterinary use, $416k/mo fee from Sep 2024
--------------------------------------------------------------------------------

- Amendment expands field of use to include veterinary uses; initial term extended to 5 years if $6M paid.
- Sublicense royalty reduced from 30% to 20%; monthly maintenance fee of $416,667 starts Sep 2024.
- Factor’s termination rights for non-sublicensed patents eliminated; CEO Matthew Angel is co-founder of Factor parent.
- Amendment considered a related-party transaction due to CEO's role at Factor Bioscience Inc.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/748592/000114036123034310/0001140361-23-034310-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/748592/000114036123034310/brhc20055786_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-034310

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer